Michael Wyatt to Antineoplastic Agents
This is a "connection" page, showing publications Michael Wyatt has written about Antineoplastic Agents.
Connection Strength
1.218
-
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
Score: 0.454
-
PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
Score: 0.225
-
Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol. 2008 Sep 15; 76(6):697-706.
Score: 0.184
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
Score: 0.116
-
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 01; 105:23-33.
Score: 0.078
-
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
Score: 0.072
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.072
-
Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89.
Score: 0.017